Hunan Nucien Pharmaceutical Co (SHSE:688189) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688189 Hunan Nucien Pharmaceutical Co Ltd SHSE:688189
47 GF Score
Price ¥6.88
GF Value ¥3.18
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Hunan Nucien Pharmaceutical Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Hunan Nucien Pharmaceutical Co is: High Risk: High uncertainty with risk-return tradeoff.

Hunan Nucien Pharmaceutical Co  (SHSE:688189) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Hunan Nucien Pharmaceutical Co Risk Assessment Related Terms

SHSE:688189 vs ZTS: Risk Assessment Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Nucien Pharmaceutical Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hunan Nucien Pharmaceutical Co Risk Assessment vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hunan Nucien Pharmaceutical Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Hunan Nucien Pharmaceutical Co's Risk Assessment falls into.


SHSE:688189
47GF Score
Hunan Nucien Pharmaceutical Co Ltd SHSE:688189
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Hunan Nucien Pharmaceutical Co (SHSE:688189) Overvalued in 2026?

Based on GuruFocus' analysis, Hunan Nucien Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥6.88 is trading 116.4% above its estimated GF Value™ of ¥3.18. GuruFocus considers Hunan Nucien Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for SHSE:688189:

  • Risk Assessment:
  • GF Value™: ¥3.18 vs. price of ¥6.88 (116.4% above fair value)
  • GF Score™: 47/100 with 2 warning signs

No single metric tells the full story. See the SHSE:688189 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hunan Nucien Pharmaceutical Co Business Description

Address No. 1 Kangli Road, Liuyang Economic and Technological Development Zone, Hunan Province, Changsha, CHN, 510100
Hunan Nucien Pharmaceutical Co Ltd is a pharmaceutical company integrating drug research and development, production and sales. The company focuses on anti-infection, cardio-cerebral vascular, anti-tumor and other pharmaceutical fields. The company's business scope includes the manufacturing and sales of chemical pharmaceutical preparations, chemical pharmaceutical raw materials, biological drugs, chemical reagents, and auxiliaries.
47GF Score

Get the complete analysis for SHSE:688189

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥6.88
Price
¥3.18
GF Value